Section 56 Exemptions Under Canada's CDSA: What Sponsors and CROs Need to Know Before Starting a Psychedelic Clinical Trial

Running a psychedelic-assisted therapy trial in Canada comes with a regulatory reality that catches a surprising number of experienced sponsors off guard: you need two approvals from Health Canada, running on two separate tracks, managed by two different directorates. The Clinical Trial Application satisfies the Food and Drug Regulations. The Section 56 exemption satisfies the Controlled Drugs and Substances Act. Miss either one — or let one lag too far behind the other — and your trial cannot lawfully proceed, regardless of how thorough your protocol is.

Since 2020, Health Canada has granted a growing number of Section 56 exemptions for psilocybin, MDMA, and other Schedule III controlled substances in therapeutic and clinical research contexts. That growth has drawn sponsors and contract research organizations into the Section 56 process for the first time. Many weren’t prepared for it.

What Section 56 of the CDSA Actually Authorizes

Section 56(1) of the Controlled Drugs and Substances Act gives the Minister of Health authority to exempt any person or class of persons — or any controlled substance or precursor — from any provision of the Act or its regulations. In plain terms: it’s a legal mechanism to permit activities that would otherwise be prohibited under Canada’s drug control regime.

For a clinical research context, that means authorization to possess, produce, import, export, distribute, and administer a controlled substance in a research setting. Without a valid Section 56 exemption, every one of those activities is a criminal offence under the CDSA, regardless of your scientific intent or your CTA status.

Exemptions are administered by Health Canada’s Office of Controlled Substances (OCS), which sits within the Controlled Substances and Cannabis Branch. Critically, OCS is not the same group reviewing your CTA. The Therapeutic Products Directorate handles CTAs; OCS handles Section 56. The two processes share no formal coordination mechanism, which means the timing burden falls on you as sponsor.

One thing that often surprises sponsors familiar with the US regulatory landscape: psilocybin and psilocin are listed as Schedule III substances under Canada’s CDSA — not Schedule I, as they are in the United States. MDMA and MDA are also Schedule III in Canada. This matters because the GMP documentation requirements, security standards, and import licensing categories differ by schedule. Schedule III substances in clinical quantities typically require secure storage meeting Health Canada’s Directive on Physical Security for Controlled Substances. For amounts above certain site-specific thresholds, that generally means a combination or key-locked steel safe with defined anchoring requirements — but your site risk assessment will determine the exact specifications.

The Dual-Track Problem: Coordinating Your CTA and Section 56

Here’s where most first-time sponsors run into real trouble. Under Division 5 of the Food and Drug Regulations — specifically Section C.05.006 — Health Canada has 30 days to review and respond to a CTA. If no objection is raised within 30 days of formal acknowledgement, the sponsor may proceed. That’s a reasonably predictable window.

The Section 56 process carries no equivalent statutory clock. Health Canada’s OCS processes applications as efficiently as possible, but complex research exemptions — particularly those involving novel psychedelic-assisted protocols with multiple sites — can take considerably longer than 30 days. Sponsors who file their CTA and Section 56 concurrently sometimes find that trial authorization under the FDR arrives well before the Section 56 is in hand. A CTA alone does not authorize possession or administration of a controlled substance. Both must be active before a patient receives a single dose.

The practical implication: file your Section 56 application at least 60 to 90 days before your anticipated site activation date, and ideally before or simultaneously with your CTA. If you’re planning a multi-site trial spanning 3 or more provinces, consider whether you need individual exemptions for each Principal Investigator, or whether a sponsor-level class exemption covering named personnel at authorized sites is achievable. The OCS will advise on the appropriate exemption structure during pre-submission consultation — and that consultation is worth requesting before you draft a single page of your application.

Protocol amendments add another layer of complexity. Any material change to the quantities of controlled substance used, the handling personnel, or the site list typically requires an amendment to your Section 56 exemption, not just a protocol amendment notice to TPD. Running those amendment tracks in parallel demands explicit project management attention that most standard CRO trial management templates don’t account for.

GMP for Schedule III Clinical Trial Materials: What Your CMO Needs to Meet

Regardless of the Section 56 exemption, clinical trial materials manufactured for Canadian trials must comply with Division C.02 of the Food and Drug Regulations. Your manufacturing site — whether domestic or foreign — needs a Drug Establishment Licence (DEL) that covers the relevant activities. For a CMO producing Schedule III controlled substances for clinical trials, that DEL must explicitly include authorization for handling that specific controlled substance category.

This is where many sponsors encounter a genuine bottleneck. Not every CMO holding a valid GMP certificate and DEL is licensed for Schedule III manufacture. Identifying a CMO that is both GMP-compliant to Canadian standards and authorized for your controlled substance category requires early due diligence — before you’ve signed a manufacturing agreement.

Foreign CMOs add another layer of complexity. Their facilities may be GMP-certified to ICH Q7 or EU GMP standards, which Health Canada generally accepts for API manufacture, but the import of a Schedule III substance into Canada requires an import permit issued by OCS under Part 3 of the CDSA Narcotic Control Regulations or Benzodiazepines and Other Targeted Substances Regulations, depending on the specific compound. Import permits are substance-specific and quantity-specific. If your clinical supply plan involves multiple shipments across multiple sites over a 2-year trial duration, each shipment event may require a separate import authorization or a standing import permit covering a defined annual quantity. That permitting process runs through OCS — again, entirely separately from TPD.

The recommendation: map every regulatory touch point across the DEL, the Section 56 exemption, the import permit, and the CTA into a single timeline. In our team’s experience supporting CROs on complex CNS-focused Canadian trials, the DEL amendment and OCS licensing for the CMO is almost always the longest lead-time item. Six months of lead time for a DEL amendment covering a new Schedule III activity is not an unusual expectation. Starting that process last — after the CTA is already filed — is the most common planning error we see.

What the Section 56 Application Needs to Contain

OCS does not publish a mandatory application form, but their guidance and the information reflected in publicly available exemption decisions make the content requirements fairly clear.

You’ll need to provide a detailed scientific rationale establishing why the research requires a controlled substance and cannot be conducted with a non-controlled alternative. This isn’t a perfunctory paragraph — OCS reviewers look for genuine justification that the exemption is necessary for legitimate scientific or medical purposes, with reference to the existing evidence base for the compound in question.

A well-constructed application documents:

• The identity and quantity of each controlled substance, broken down by site and anticipated patient exposure over the trial duration
• The names, roles, and professional qualifications of all individuals who will handle the substance (possession under an exemption is personal — unnamed personnel are not covered)
• Security measures at each site, matched to Health Canada’s physical security directive requirements for the relevant schedule and quantity
• Disposal and waste procedures, including what happens to unused clinical material at trial close-out or early termination
• Adverse event and unexpected use reporting commitments under both the CDSA framework and your CTA safety reporting obligations under Division 5

One area OCS scrutinizes closely is inventory accountability. Your trial site SOPs need to include a controlled substance log that tracks every unit from receipt through administration or destruction. This is a GMP expectation that maps directly to your Division C.02 requirements, but OCS treats it as a CDSA compliance matter as well. A missing or inconsistent controlled substance inventory reconciliation can follow you into your next exemption application.

The Special Access Program: A Parallel Mechanism Worth Understanding

Canada’s Special Access Program was amended in January 2022 to allow regulated healthcare practitioners to request controlled substances — including psilocybin — for individual patients outside of formal clinical trials. This operates under a separate regulatory authority from Section 56, and it’s not a pathway for conducting structured research with a protocol and enrolled cohort.

For trial sponsors, the SAP has limited relevance to formal study design. But contextually, it matters: the existence of SAP access has created a small and growing cohort of Canadian patients and prescribers with real-world psilocybin administration experience. Some clinical sites that have participated in SAP-authorized psilocybin cases have developed institutional SOPs for controlled substance handling that can be adapted to a trial context with relatively modest effort. Starting with an experienced site isn’t just operationally faster — it’s a meaningful risk reduction for your Section 56 security and accountability commitments.

Before You File: Three Things to Do First

The Section 56 process rewards preparation. Before you submit anything to OCS, take three concrete steps.

Request a pre-submission meeting. Health Canada’s OCS will accommodate pre-submission consultations for complex research exemptions. A 30 to 45-minute call can clarify the appropriate exemption structure, surface documentation gaps before submission, and establish a working relationship with reviewers who will assess your application. Most sponsors who skip this step end up having the same conversation later — after a deficiency notice has already introduced a delay.

Confirm your CMO’s DEL authorization before committing to a manufacturing timeline. Verify in writing that the DEL covers the specific CDSA schedule of your compound and the specific activities you require. If an amendment is needed, initiate it now. Six months is a reasonable minimum planning horizon for a DEL amendment covering a new Schedule III activity at a Canadian facility.

Align your controlled substance quantities at the SKU level before finalizing your protocol. Dosage escalations, protocol amendments that add patient cohorts, or site additions that push you above the quantity ceiling in your Section 56 exemption all require an amendment — creating a dependency between protocol development and exemption administration that teams don’t always anticipate. Build a quantity buffer into your application from the outset.

Canada’s psychedelic clinical trial landscape is developing quickly, and Health Canada has demonstrated genuine willingness to facilitate legitimate research while holding a firm line on procedural compliance. The sponsors and CROs who activate on schedule are the ones who treat the Section 56 process with the same rigour they give to their CTAs — not as a secondary administrative task, but as an equal pillar of their regulatory strategy.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• GMP-compliant analytical testing for Canadian pharmaceutical submissions — Qalitex Laboratories provides ISO 17025-accredited testing services supporting CTA and NDS filings across a broad range of drug classes.
• EU regulatory strategy for sponsors pursuing dual Canada-Europe approvals — Care Europe advises on EU 536/2014 clinical trial regulation and EMA submission strategy for sponsors seeking multi-jurisdictional market access.